Anti-amyloid drug data readout drives up APOE testing

Interesting finding by Truveta. A 125% increase of APOE4 status testing rate during 09/22-01/23 period vs. 09/21-01/22, possibly due to lecanemab Ph3 data readout.

It makes me wonder whether there's increased demand for tau PET imaging since donanemab Ph3 data readout a few weeks ago, although tau PET is unlikely to be reimbursed currently, so we might not see any impact on the testing rate yet.

#alzheimersdisease#biogen#elililly#tau#APOE4

https://www.truveta.com/blog/research/apoe4-genetic-testing/?utm_source=linkedin&utm_medium=paid&utm_campaign=awareness&utm_term=truvetaresearch&utm_content=alzheimersapoe4&hsa_acc=504956744&hsa_cam=635347503&hsa_grp=227596403&hsa_ad=248755643&hsa_net=linkedin&hsa_ver=3